Retevmo Tablet, Coated
Product Images NDC 0002-5562

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Retevmo (NDC 0002-5562). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Retevmo Uspi Chem)

Chemical structure of selpercatinib, the active ingredient in RETEVMO. The diagram shows the molecular framework with nitrogen-containing heterocycles and functional groups relevant to its chemical composition.*

FDA Label Image

Figure 1 (Retevmo Uspi F1 V1)

A Kaplan-Meier curve illustrating progression-free survival probability over time from randomization in months. The chart compares RETEVMO (selpercatinib) and chemotherapy with pembrolizumab, showing higher progression-free survival probability for RETEVMO. The number of patients at risk is listed below the x-axis at various time points up to 36 months.*

FDA Label Image

Figure 2 (Retevmo Uspi F2 V1)

A Kaplan-Meier survival curve chart showing progression-free survival probability over time in months from randomization. The chart compares two patient groups: one treated with Selpercatinib (N=193) and another treated with Cabozantinib or Vandetanib (N=98). Selpercatinib shows a higher progression-free survival probability over the study period. Censored observations and the number of patients at risk at various time points are also displayed.*

FDA Label Image

Retevmo 40mg Capsules (60 Count Bottle)

Retevmo 40 mg capsules label showing the product name and strength with the active ingredient selpercatinib. The label indicates each capsule contains 40 mg of selpercatinib, includes storage instructions, and states the package contains 60 capsules. The labeler is Eli Lilly and Company.*

FDA Label Image

Retevmo 80 mg Capsules (60 Count Bottle)

The label for Retevmo 80 mg capsules containing selpercatinib. The label indicates 60 capsules in the package, for oral use, prescription only. It includes storage instructions, manufacturer Eli Lilly and Company, and a website www.retevmo.com. The concentration of active ingredient per capsule is 80 mg.*

FDA Label Image

Package Label – Retevmo 40mg Tablets (60 Count Bottle)

Label for RETEVMO (selpercatinib) 40 mg oral tablets by Eli Lilly and Company. The label indicates a 60 tablet count and includes storage instructions, caution to keep out of reach of children, and directions to refer to prescribing information. The product is marketed by Lilly USA LLC in Indianapolis.*

FDA Label Image

Package Label – Retevmo 80mg Tablets (60 Count Bottle)

Label for Retevmo (selpercatinib) tablets, 80 mg strength. The label indicates a package containing 60 tablets, intended for oral use. Labeler is Eli Lilly and Company, with storage instructions and warnings about seal integrity. The label includes the NDC number, a barcode, and the company logo.*

FDA Label Image

Package Label – Retevmo 120mg Tablets (60 Count Bottle)

Label for Retevmo 120 mg tablets containing selpercatinib, an oral prescription drug by Eli Lilly and Company. The label indicates a package of 60 tablets with storage instructions, manufacturer details, and a National Drug Code (NDC 0002-6120-60) shown.*

FDA Label Image

Package Label – Retevmo 160mg Tablets (60 Count Bottle)

Label for Retevmo (selpercatinib) oral tablets, 160 mg strength, supplied in a package of 60 tablets. The label shows the NDC number 0002-5562-60 and indicates the product is marketed by Eli Lilly and Company, USA. It includes storage instructions and a barcode, with the brand and generic names prominently displayed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.